Are We Gearing up for Biological Warfare?

Thank you for Seth Shulman's useful article on military funding for research on biological warfare (BW) (The Scientist, December 15, pp. 1, 8). It is highly significant that between 1981 and 1987—the Reagan years—Department of Defense funding for BW has gone up by a factor of five. Let us recall also that in his status as President of the Senate, Vice President George Bush twice broke a tie vote on the production of binary nerve gases, both times in favor of producing them. One of th

Written byGeorge Wald
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

One of the most frequent ploys in encouraging public acceptance of weapons programs is to present them as defensive. Shulman's article states that "most of this research focuses on the development of vaccines against some of the most deadly and exotic diseases known—diseases that could be unleashed as part of a biological warfare (BW) campaign."

In this field, defense and offense go hand in hand. No nation would dare unleash such disease without first taking the precaution to immunize its own population. A few years ago, the Federation of American Scientists published a Public Interest Report discussing the possibility of recombinant DNA's contributing to BW. The article noted that if any nation proceeded to immunize its population against some disease, that action could be taken as a warning that it was about to launch a BW attack.

At the time I wondered whether this concept reflected our own attempt in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies